DISRUPT CAD II

By The Numbers

120
Patients
30
Day Follow-up
15
European Sites
MACE
In-Hospital = Primary Safety Endpoint
<50%
Residual Stenosis = Primary Performance Endpoint

DISRUPT CAD II Study Leadership

jean fajadet
Dr. Jean Fajadet
Co-Principal Investigator
Clinique Pasteur
Toulouse, France
carlo di mario
Dr. Carlo di Mario
Co-Principal Investigator
AOU Careggi SOD Interventistica
Firenze, Italy

Countries Included in DISRUPT CAD II

Europe
Sweden

Dr. Stefan James
Uppsala University Hospital
Uppsala, Sweden

Denmark

Dr. Evald Christiansen
Aarhus Universitetshospital
Aarhus, Denmark

Netherlands

Dr. Nicolas van Mieghem
Thorax Center, Erasmus MC
Rotterdam, Netherlands

 

Dr. Elvin Kedhi
Isala Zeikenhuis- Hartecentrum
Zwolle, Netherlands

United Kingdom

Dr. Jonathan Hill
King's College Hospital
London, United Kingdom

 

Dr. Adrian Banning
Oxford University Hospitals,
John Radcliffe Hospital
Oxford, United Kingdom

Germany

Dr. Miroslaw Ferenc
Universitaets-Herzzentrum Freiburg- Bad Krozingen
Bad Krozingen, Germany

 

Dr. Nikos Werner
Universitaetsklinikum Bonn
Bonn, Germany

 

Dr. Holger Nef
UKGM Universitaetsklinikum Giessen
Gießen, Germany

Belgium

Dr. Bernard De Bruyne
Onze-Lieve-Vrouwziekenhuis
Aalst, Belgium

France

Dr. Jean Fajadet
Clinique Pasteur
Toulouse, France

 

Dr. Thierry Lefevre
Institut Hospitalier Jacques Cartier
Massy, France

Spain

Dr. Javier Escaned
Hospital Universitario San Carlos
Madrid, Spain

Italy

Dr. Carlo Di Mario
AOU Careggi SOD Interventistica
Firenze, Italy

 

Prof. Matteo Montorfano
San Raffaelle Hospital
Milan, Italy

Ready to Make Waves with Shockwave IVL?

ico email Connect